DeLorean Artificial Intelligence, a Miami-based AI technology development company, has raised $7.55 million in Series A funding. The round, which brought the company's total funding to approximately $11 million, was led by Sopris Venture Capital, with participation from Pinta Capital Partners and James Chow.
The company plans to use the new funds to accelerate the expansion and adoption of its Medical AI product in the United States, Europe, the Middle East, and Latin America. Medical AI is a predictive analytics platform that uses machine learning to create mathematical profiles of patient journeys and treatment methodologies. The platform can help doctors and other healthcare providers make more informed decisions about patient care. In addition to Medical AI, DeLorean AI has developed several other proprietary AI capabilities, including CPG Sales AI, TAPE AI, and CRM AI. CPG Sales AI is a platform that helps consumer packaged goods (CPG) companies optimize their sales and marketing campaigns. TAPE AI is a platform that helps businesses analyze service tickets to identify trends and patterns. CRM AI is a platform that helps businesses predict the winnability of deals and their financial impacts on revenue generation and costs.
DeLorean AI is led by CEO and Founder Dr. Severence MacLaughlin. Dr. MacLaughlin is a former executive at Capgemini Invent and Cognizant, where he led the development of AI solutions for healthcare and life sciences companies. The company's investors are bullish on the potential of DeLorean AI's AI capabilities to address a wide range of business challenges. Sopris Venture Capital Managing Partner Jim Anderson said, "We are excited to partner with DeLorean AI to bring their innovative AI solutions to market. We believe that their products have the potential to transform the way businesses operate."
